Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4302814 in Healthy Participants
NCT07566338Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY4302814 (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration. Started May 2026; status: recruiting.
02
Drugs
LY4302814
Beyond the preview
Go deeper on NCT07566338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566338.